Bayer/J&J report positive Xarelto results in Japanese AF patients
This article was originally published in Scrip
Executive Summary
Bayer and Johnson & Johnson have revealed data that formed part of its Japanese submission package for the oral daily anticoagulant Xarelto (rivaroxaban) for the prevention of stroke in patients with atrial fibrillation. The results, which were presented at the 23rd Congress of the International Society on Thrombosis and Haemostasis in Kyoto, Japan, showed that the product met the primary endpoint in a Japanese Phase III atrial fibrillation study, by demonstrating non-inferior safety compared with warfarin.